Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 901–1,000 of 1,733
Daneshnia, N., Chechko, N., & Nehls, S. (2024) · Clinical Child and Family Psychology Review · doi:10.1007/s10567-024-00474-7 · Cited by 15
Lin, B., & Twigg, S. M. (2023) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-22-0242 · Cited by 5
Pituitary function in patients with primary and secondary empty sella
Steckel, L., Gizewski, E. R., & Kaser, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1632824 · Cited by 4
CANNARELLA, R., CALOGERO, A. E., CONDORELLI, R. A., GRECO, E. A., Aversa, A., & VIGNERA, S. L. (2022) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03600-9 · Cited by 4
Lofrano‐Porto, A., Soares, E. D. M. K. V. K., Matias, A. A., Porto, L. G. G., & Smith, D. L. (2020) · Andrology · doi:10.1111/andr.12860 · Cited by 4
Porto, L. G. G., Soares, E. D. M. K. V. K., Ranadive, S. M., Lofrano‐Porto, A., & Smith, D. L. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21030274 · Cited by 6
“Symptoms associated with sustained low TT include fatigue, increased body fat, and lowered fat muscle mass [21,22].”
BackgroundMethodInfluentialThe TRAVERSE trial: cardiovascular safety of testosterone therapy for older men
Anawalt, B. D. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00254-1 · Cited by 6
Implementation of a Pilot Pharmacist Testosterone Therapy Management Service
Nagy, M. W., Gruber, S., & McConnell, M. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019830251 · Cited by 4
“Of note, per Endocrine Society Guidelines, testosterone replacement should be monitored every 3 to 6 months after initiation and dose changes.(9) As this was a pilot project, future analysis can extend the follow-up period to evaluate long-term impact of the service.”
BackgroundMethodInfluentialEffect of SARS-CoV-2 infection on sperm telomere length
Soares, M. R., de Carvalho, R. M., Cirino, H. S., Júnior, R. B. M., Furtado, C. L. M., Santana, B. A., Calado, R. T., Ferriani, R. A., & dos Reis, R. M. (2025) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-025-03408-6 · Cited by 4
“Of the 112 subjects, 76 (67.85%)—equally divided into 38 subjects in each positive and negative group—had a free testosterone level above the lower limit of 300 ng/ dl [29], and the testosterone/estradiol (T/E) ratio mean of 17.12 ± 5.22.”
InfluentialDevelopments and challenges for new and emergent preparations for male hypogonadism treatment
Corona, G., Sparano, C., Rastrelli, G., Vignozzi, L., & Maggi, M. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2276760 · Cited by 4
“…hypogonadism, because, in this case, treating the underlying metabolic condition, with lifestyle measures (e.g. physical exercise), or even bariatric surgery, is efficient in restoring normal T levels [20,21,24,25] and is recommended as the first approach by some of the available guidelines [3,6].”
BackgroundMethodResultInfluentialErectile Dysfunction in Patients with Multiple Chronic Conditions: A Cross- Sectional Study
Giagulli, V. A., Lisco, G., Bartolomeo, N., Ramunni, M. I., Tullio, A. D., Carbone, M. D., Guastamacchia, E., Pergola, G. D., & Triggiani, V. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220523130212 · Cited by 7
Zucker, I. J., & Masterson, T. A. (2021) · International Journal of Impotence Research · doi:10.1038/s41443-021-00477-w · Cited by 4
Zitzmann, M., Soave, A., & Bier, S. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.108870 · Cited by 10
Hypogonadism and its treatment among prostate cancer survivors
Choi, E. J., Xu, P. J., El‐Khatib, F. M., Huynh, L. M., & Yafi, F. A. (2020) · International Journal of Impotence Research · doi:10.1038/s41443-020-00387-3 · Cited by 5
de Velasco, L. M. C., & Flores, J. E. G. (2025) · Cureus · doi:10.7759/cureus.92778 · Cited by 7
Nieschlag, E., & Behre, H. M. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-61901-8_36 · Cited by 2
Sexual behavior in men during COVID-19
Fácio, F. N., Facio, M. F. W., Spessoto, A. C. N., & Spessoto, L. C. F. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.12.1613 · Cited by 4
Assessing men with opioid use disorder for testosterone deficiency after the development of symptoms
Bali, B., Tuan, W., Scott, A. R., Bollampally, P., Groff, D., Leong, S. L., King, V. L., & Bone, C. (2024) · Journal of Addictive Diseases · doi:10.1080/10550887.2024.2327751 · Cited by 4
“7 17–19 However, a recent study demonstrated that evaluation for testosterone deficiency did not occur in more than 80% of people that received long term opioid treatment in the United States.”
Late-onset hypogonadism: current methods of clinical diagnosis and treatment in Japan
Amano, T. (2025) · Asian Journal of Andrology · doi:10.4103/aja2024111 · Cited by 6
Reid, K. F., Storer, T. W., & Bhasin, S. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18293 · Cited by 4
“In phase 2 and 3 trials of testosterone, SARMs, and myostatin/ activin blockers, the leading candidate drugs that have undergone the most extensive studies, the overall frequency of drug-related adverse events has been low.(21,22) Erythrocytosis is the most frequent adverse event associated with testosterone treatment…”
BackgroundSelf-citationIuliano, S., Greco, F., Seminara, G., Zagari, M. C., Sgrò, P., Gennaro, G. D., Greco, E. A., & Aversa, A. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04024-1 · Cited by 5
Adult Male Hypogonadism: A Laboratory Medicine Perspective on Its Diagnosis and Management
Livingston, M. A., & Heald, A. H. (2023) · Diagnostics · doi:10.3390/diagnostics13243650 · Cited by 9
“Regarding other investigations, in men with T levels 5.2 nmol/L and increased prolactin levels or reduced LH and FSH levels, pituitary magnetic resonance imaging (MRI) should be performed to exclude a pituitary adenoma/empty sella [45,51].”
BackgroundInfluentialThe Association of Free Testosterone Levels With Frailty Metrics in Advanced Chronic Liver Disease
Sogbe, M., Bromfield, B. B., Tellez, R., Bloomer, P. M., Herrera-Caceres, J. O., Hughes, C. B., Dunn, M. A., & Duarte‐Rojo, A. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002192 · Cited by 4
Zamir, A., Ben‐Zeev, T., Levi, C., Einstein, O., Ratamess, N. A., van Praag, H., & Hoffman, J. R. (2023) · Hormones and Behavior · doi:10.1016/j.yhbeh.2023.105444 · Cited by 4
Diagnosis and treatment of hypogonadism in men seeking to preserve fertility – what are the options?
Lockie, A. W. C., Grice, P., Mathur, R., Pearce, I., & Modgil, V. (2024) · International Journal of Impotence Research · doi:10.1038/s41443-024-00897-4 · Cited by 4
“These formulations are not an appropriate option for those who wish to maintain fertility [35].”
Plasma metabolomics in male primary and functional hypogonadism
Grande, G., Toni, L. D., Garolla, A., Milardi, D., & Ferlin, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1165741 · Cited by 6
Ben‐Zeev, T., Levi, C., & Hoffman, J. R. (2025) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003799 · Cited by 5
Endocrine Disorders Accompanying Obesity - Effect or Cause?
Kuryłowicz, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98793 · Cited by 8
Female Testosterone: Contested Terrain
Krane, V., Calow, E., & Panunti, B. A. (2021) · Kinesiology Review · doi:10.1123/kr.2021-0062 · Cited by 6
Protocolo de evaluación del hipogonadismo en el varón adulto y en el anciano
Ortiz-Flores, A. E., Corrales, E. P., Castro, M. A., & Escobar-Morreale, H. F. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.10.007 · Cited by 5
Endocrinological diagnosis and replacement therapy for hypopituitarism
Espósito, D., Johannsson, G., & Ragnarsson, Ó. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819949-7.00027-5 · Cited by 7
Antonič, K. G., Antonič, B., & Pfeifer, M. (2020) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0008 · Cited by 5
“4,27,28 We performed one additional check each year of the study during the first 6 months to get more detailed insight into how Hct and PSA levels respond to introduction of TTh, resulting in three safety tests per each year of the study (at baseline, approximately at 3, 6, and 12 months into each…”
InfluentialCorona, G., Goulis, D. G., & Liu, P. Y. (2023) · Clinical Endocrinology · doi:10.1111/cen.14941 · Cited by 4
Hoai, B. N., Truong, T. Đ., Thắng, N. C., Pham, Q. M., & Nguyen, V. B. D. (2024) · The Aging Male · doi:10.1080/13685538.2024.2422379 · Cited by 3
Vichuladda, V., Suwan, A., Panyakhamlerd, K., et al. (2025) · International Journal of Transgender Health · doi:10.1080/26895269.2025.2483214 · Cited by 3
D’Andrea, S., Castellini, C., Minaldi, E., Totaro, M., Felzani, G., Francavilla, S., Francavilla, F., & Barbonetti, A. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01243-3 · Cited by 4
Nolan, B. J., Proietto, J., & Sumithran, P. (2022) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.62770 · Cited by 2
“Standard doses and formulations to those given to hypogonadal men without PWS are typically administered (Bhasin et al., 2018; Tauber & Hoybye, 2021), though there are no supportive data using these doses and formulations in individuals with PWS. Limited data have demonstrated improvements in bone…”
BackgroundInfluentialPetry, C., Minuzzi, R. K., dos Santos, F. S., Semmelmann, A. L., Bassols, G. F., & Lima, J. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07626-2 · Cited by 4
“To characterize hypog-onadism, the cut-off point was considered for TT <264 ng/ dL, according to the Endocrine Society [10]; when SHBG was low, FT was calculated, and the cut-off point was 6.5 ng/dL.”
InfluentialHypogonadism in HIV infection: time to fine-tune clinical monitoring of persons with HIV?
Gharakhanian, S., & Wit, S. D. (2022) · AIDS · doi:10.1097/qad.0000000000003256 · Cited by 3
Clinical significance of sex hormones in COVID-19
Nasser, M., & Soma, W. (2020) · Journal of Gynecological Research and Obstetrics · doi:10.17352/jgro.000088 · Cited by 3
“A second possibility is that hypogonadism is common in patients with COVID-19 as result of co-morbidities such as diabetes, obesity, obstructive sleep apnea [17].”
BackgroundBathina, S., Lopez, V. F., Prado, M., Ballato, E., Colleluori, G., Tetlay, M., Villareal, D. T., Mediwala, S. N., Chen, R., Qualls, C., et al. (2024) · Physiological Reports · doi:10.14814/phy2.70124 · Cited by 4
“One-hundred and five of the participants (47/92 among AA and 58/101 among NAA) had low testosterone (i.e., 264 ng/dL) according to the Endocrine Society Guidelines (Bhasin et al., 2018), but there was no significant difference in the number of patients with low testosterone between the groups.”
Agbecha, A., & Saa-Aondo, G. J. (2019) · Biochemistry and Molecular Biology · doi:10.11648/j.bmb.20190401.11 · Cited by 3
“In scenarios in which the patient has a clear pathophysiologic mechanism for the hypogonadism, treatment with testosterone is nearly always recommended to alleviate symptoms of hypogonadism and maintain secondary sexual characteristics [1].”
BackgroundAdams, M. R., Pijut, K. D., Uttal-Veroff, K. C., & Davis, G. A. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900211073286 · Cited by 3
“The US Endocrine Society practice guidelines recommend against starting testosterone therapy in patients who present with elevated hematocrit above the upper limit of normal, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months or thrombophilia due to increased risk of thrombotic events…”
BackgroundMethodInfluentialYang, L., Zhang, Y., Chen, X., Liu, K., Zhou, Y., & Wang, S. (2024) · Clinical Endocrinology · doi:10.1111/cen.15075 · Cited by 4
“Basal evaluation criteria of pituitary function were performed as we described previously 6,12,13 before exogenous glucocorticoids used.”
Gonadal Function in Male Patients With Metastatic Renal Cell Cancer Treated With Sunitinib
Volta, A. D., Delbarba, A., Valcamonico, F., Cappelli, C., Caramella, I., Bergamini, M., Ferlin, A., & Berruti, A. (2023) · In Vivo · doi:10.21873/invivo.13093 · Cited by 5
Choi, E. J., Xu, P. J., El‐Khatib, F. M., Kavoussi, P. K., & Yafi, F. A. (2021) · International Journal of Impotence Research · doi:10.1038/s41443-021-00435-6 · Cited by 3
Çelik, M., Özçelik, S., Baş, S., Sarıaydın, M., Özçelik, M., & Gözü, H. I. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000399 · Cited by 5
“Male sexual dysfunction, including decreased libido, erectile dysfunction, and abnormal ejaculation is a common type of health disorder (15-17).”
Lanzi, V., Indirli, R., Tripodi, A., Clerici, M., Bonomi, M., Cangiano, B., Petria, I., Arosio, M., Mantovani, G., & Ferrante, E. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae317 · Cited by 5
Andriuskeviciute, A., Cossu, G., Ameti, A., Papadakis, G. E., Daniel, R. T., Dunet, V., & Messerer, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.890853 · Cited by 4
Soliman, A. R., Ahmed, R. M., Meligi, A. A. H. E., Abo-Zeid, A. G., Amer, M. A., Atef, A., Yousry, A., Saleh, A. A., Fahmy, E. M., Makar, W., et al. (2025) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-025-00513-x · Cited by 3
“Other causes of hypogonadotropic hypogonadism should be excluded before attributing the hormonal disorder to obesity [23].”
Management of hematocrit levels for testosterone replacement patients, a narrative review
Fink, J. E., Bentzen, K., & Horie, S. (2025) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeaf013 · Cited by 4
Benefits and risks of testosterone therapy in older men
Attard, C. C., & Fava, S. (2019) · Minerva Urologica e Nefrologica · doi:10.23736/s0393-2249.19.03301-0 · Cited by 3
Beyond T-Trials, T4DM and TRAVERSE: the next large testosterone randomized controlled trial
Yeap, B. B., Tran, C., Douglass, C. M., & McNeil, J. J. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000886 · Cited by 6
Hsieh, T., Chang, C.-W., Chen, C.-Y., Lin, C.-Y., Geng, J., Huang, S., Lee, Y., Juan, Y., Wu, W., & Liu, C. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117642 · Cited by 3
Carlier, L., Chanson, P., Cazabat, L., Daclin, S., Salenave, S., Hage, M. P., Trabado, S., Young, J., & Maione, L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae135 · Cited by 4
“In men, high circulating prolactin levels, like those found in patients harboring a PSPA, are associated with TD, a morbid syndrome characterized by a range of signs and symptoms, and with several long-term clinical consequences [11, 12, 14].”
BackgroundMethodInfluentialTestosterone Replacement in Men With Hypogonadism and Effects on Anemia—Blood, Sex, and Aging
Alibhai, S. M. H. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.39969 · Cited by 3
Foster, J., Wright, P., Rao, P. M., Edwards, D., Greenwood, M., Wayman, R., Singh, I., Fortes-Mayer, G., & Barber, T. (2025) · The Journal of Sexual Medicine · doi:10.1093/jsxmed/qdaf130 · Cited by 4
Varlamov, E. V., & Fleseriu, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00019-6 · Cited by 6
Cox, L. T. J., & Khan, I. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01321-w · Cited by 7
“The decision to initiate TRT is typically based on both clinical symptoms and biochemical confirmation of low serum testosterone levels (i.e., blood tests) [8, 9, 90, 103], with normal ranges generally defined as 8–29 nmol/L.”
Male infertility: before and after the era of SARS-CoV-2
Ovchinnikov, R. I., Gamidov, S. I., Popova, A. Y., & Ижбаев, С. Х. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-13-179-187 · Cited by 4
Male Hypogonadism (According to the Materials of the European Association of Urology)
Gorpynchenko, I., Gurzhenko, Y., & Spyrydonenko, V. (2022) · Health of Man · doi:10.30841/2307-5090.4.2022.274432 · Cited by 3
“Рівні fT <225 пмоль/л (6,5 нг/дл) пов’язані з гіпогонадальними симптомами [6, 37, 66, 67].”
Grossmann, M. (2023) · Clinical Endocrinology · doi:10.1111/cen.14932 · Cited by 3
Prevalence and clinical associations with primary hypogonadism in male systemic sclerosis
Thepwiwatjit, S., Charoensri, S., Sirithanaphol, W., Mahakkanukrauh, A., Suwannaroj, S., & Foocharoen, C. (2022) · Journal of Scleroderma and Related Disorders · doi:10.1177/23971983221112021 · Cited by 3
Patnaik, N., Mishra, K. G., & Pradhan, N. R. (2022) · Cureus · doi:10.7759/cureus.26236 · Cited by 3
“The risks and benefits of testosterone therapy have been reviewed comprehensively in clinical guidelines [24-26].”
BackgroundThe Impact of Testosterone Therapy on Benign Prostatic Hyperplasia in Hypogonadal Males
Fendereski, K., Horns, J. J., Dehghanbanadaki, H., Watkins, C. M., & Hotaling, J. M. (2024) · Urology · doi:10.1016/j.urology.2024.11.006 · Cited by 4
Manestar, D., Malvić, G., Velepic, M. M., Vukelić, J., Vrebac, I., Tudor, F., Vukelić, I., & Braut, T. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104062 · Cited by 3
Long‐term testosterone undecanoate replacement therapy: Impact of ethnicity
Kempegowda, P., Quinn, L. M., Chandan, J. S., Shepherd, L. M., Kauser, S., Rahim, A., & Bates, A. T. (2020) · Clinical Endocrinology · doi:10.1111/cen.14157 · Cited by 3
Endocrine disorders linked to chronic kidney disease: Mechanisms and clinical implications
Concepción‐Zavaleta, M. J., Fuentes‐Mendoza, J. M., López-Ramírez, E. P., Martínez-García, J. A., Urteaga, L. A. C., & Paz‐Ibarra, J. (2026) · World Journal of Nephrology · doi:10.5527/wjn.v15.i1.113875 · Cited by 4
Ørnstrup, M. J., Høst, C., Rittig, N. F., & Gravholt, C. H. (2024) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00078.2024 · Cited by 3
Male Sex Hormones in Andrology Today
Bianchi, N., Prontera, O., Dicuio, M., Concetti, S., Sforza, A., & Corona, G. (2022) · Springer eBooks · doi:10.1007/978-3-031-11701-5_19 · Cited by 3
Hypogonadotropic hypogonadism as a cause of NOA and its treatment
Salvio, G., Balercia, G., & Kadıoğlu, A. (2024) · Asian Journal of Andrology · doi:10.4103/aja202483 · Cited by 7
de Velasco, L. M. C., Flores, J. E. G., & Arteaga, J. L. M. (2025) · Cureus · doi:10.7759/cureus.92538 · Cited by 4
“Testosterone replacement therapy (TRT) has therefore emerged as a therapeutic strategy to restore hormone levels and alleviate symptoms, with some evidence suggesting potential benefits in long-term health outcomes, though results remain mixed and population-dependent [3-6].”
InfluentialBhasin, S., & Snyder, P. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab246 · Cited by 3
“In hypogonadal men, who are candidates for testosterone treatment, but who are not at high risk of bone fracture, BMD should be monitored after initiating testosterone treatment (7, 8).”
BackgroundSelf-citationLawand, J. J., Mirahmadi, A., Holle, A. M., Parmar, R. P., Elias, T. J., Somerson, J. S., Hill, B. W., Khan, A. Z., Horneff, J. G., & Abboud, J. A. (2026) · Journal of Shoulder and Elbow Surgery · doi:10.1016/j.jse.2025.12.013 · Cited by 4
de Winter, D. T. C., Neggers, S. J. C. M. M., van den Heuvel‐Eibrink, M. M., & van Atteveld, J. E. (2024) · Endocrine Connections · doi:10.1530/ec-24-0487 · Cited by 3
“Additionally, sex hormone replacement carries several risks, including a slight increase in the rates of breast cancer and strokes (104, 105).”
Low Testosterone in Men With Type 2 Diabetes: The Role of Estrogen Excess and Aromatase Activity
Tun, N. N., Livingstone, D. E. W., & Gibb, F. W. (2026) · Clinical Endocrinology · doi:10.1111/cen.70098 · Cited by 3
“Low total testosterone was defined as 10 nM and low CFT was defined as 220 pM, as these values have commonly been used in clinical guidance [18] and previously published studies [19].”
Lee, D. S., & Park, H. J. (2020) · The World Journal of Men s Health · doi:10.5534/wjmh.200062 · Cited by 3
“When we reviewed the guidelines [3-8], the sources of statements on the efficacy and safety of testosterone therapy on several clinical statuses were different from one another; the range of sources was from a handful of systematic reviews to a well-designed randomized controlled trial.”
Obstructive Sleep Apnea and Testosterone Replacement Therapy
Vignera, S. L., Calogero, A. E., Cannarella, R., Condorelli, R. A., Magagnini, C. M., & Aversa, A. (2020) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0001 · Cited by 4
“18 Current guidelines recommend TRT for adult men with severely reduced testosterone levels ( 9.2 nmol/L), 19 but they suggest against its use in patients with untreated severe OSA since treating hypogonadal patients may cause an increase of apneas and hypopneas events.”
InfluentialPelusi, C., Bartolomeo, N., Lisco, G., Baccini, M., Fanelli, F., Pergola, G. D., Triggiani, V., Pagotto, U., & Giagulli, V. A. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220304110958 · Cited by 7
Fantus, R. J., Chang, C., Hehemann, M. C., Bennett, N., Brannigan, R. E., Helfand, B. T., & Halpern, J. A. (2020) · Andrology · doi:10.1111/andr.12849 · Cited by 3
Xu, X., Li, C., Diao, H., Guo, Y., Zhao, Y., Zhao, W., & Dong, B. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3718 · Cited by 4
Testosterone Therapy in Adult Men with Hypogonadism
Llahana, S. (2019) · Springer eBooks · doi:10.1007/978-3-319-99817-6_46 · Cited by 4
Genchi, V. A., Zanni, E., Colzani, M., Lauriola, C., Cignarelli, A., Santi, D., & Greco, C. (2023) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2023.06 · Cited by 4
Engle, R. L., Bokhour, B. G., Rose, A. J., Reisman, J. I., & Jasuja, G. K. (2022) · Patient Education and Counseling · doi:10.1016/j.pec.2022.10.003 · Cited by 3
Risk Factors Affecting Puberty: Environment, Obesity, and Lifestyles
de Angelis, C., Garifalos, F., Mazzella, M., Menafra, D., Verde, N., Castoro, M., Simeoli, C., Pivonello, C., Colao, A., & Pivonello, R. (2021) · Trends in andrology and sexual medicine · doi:10.1007/978-3-030-80015-4_10 · Cited by 7
Facondo, P., Delbarba, A., Pezzaioli, L. C., Ferlin, A., & Cappelli, C. (2023) · Andrology · doi:10.1111/andr.13376 · Cited by 3
de Silva, N. L., Hyams, E., Grant, B., Dixit, P., Bassi, R., Bassett, P., Comninos, A. N., & Jayasena, C. N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf488 · Cited by 4
Szuber, N., Tefferi, A., & Gangat, N. (2025) · Hematology · doi:10.1182/hematology.2025000704 · Cited by 3
Gonadal Dysfunction in Wolfram Syndrome: A Prospective StudyPreprint
Esteban-Bueno, G., & Fernández‐Martínez, J. L. (2025) · Research Square · doi:10.21203/rs.3.rs-6403130/v1 · Cited by 3
An obese 48-year-old man with progressive fatigue and decreased libido
Farkouh, A., & Zayed, A. A. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18097 · Cited by 3
DeFina, L. F., Radford, N. B., Leonard, D. S., Wilson, R. K., Cooper, T. C., Clark, S. M., Vega, G. L., Barlow, C. E., Willis, B. L., Gibbons, L. W., et al. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2019-001083 · Cited by 5
Does Testosterone Salvage PDE5i Non-Responders? A Scoping Review
Pignanelli, M., Stern, N., & Brock, G. B. (2023) · Endocrines · doi:10.3390/endocrines4010011 · Cited by 3
Longwolf, K. J., Johnson, C. E., Horns, J. J., Hotaling, J. M., & Brooke, B. S. (2023) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2023.06.035 · Cited by 3
Development and Validation of Quality Measures for Testosterone Prescribing
Borzecki, A. M., Conti, J., Reisman, J. I., Vimalananda, V. G., Nagy, M. W., Paluri, R., Linsky, A. M., McCullough, M. B., Bhasin, S., Matsumoto, A. M., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad075 · Cited by 3
Self-citationEndogenous Testosterone, Testosterone Treatment, and Cardiovascular Health Outcomes in Men
Yeap, B. B., & Anawalt, B. D. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf622 · Cited by 7
Impact of Clomiphene Citrate on the Steroid Profile in Dysmetabolic Men with Low Testosterone Levels
Pelusi, C., Fanelli, F., Baccini, M., Pergola, G. D., Triggiani, V., Mezzullo, M., Fazzini, A., Dalmazi, G. D., Petrovic, B., Paterini, P., et al. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1542-8763 · Cited by 4
Male pediatric, adolescent, and young adult reproductive survivorship
Burns, K. C., Phillips, C., Brannigan, R. E., Franklin, A. R. K., Howell, J. C., Schmidt, D., Sopfe, J., Appiah, L. A., & Anazodo, A. C. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.28823 · Cited by 5
Rivero, M., Reddy, R. S., Muthigi, A., et al. (2024) · The World Journal of Men s Health · doi:10.5534/wjmh.230164 · Cited by 3
Bouter, J., Reznik, Y., & Thariat, J. (2023) · Cancers · doi:10.3390/cancers15153820 · Cited by 4
“Hypogonadism also leads to nonspecific symptoms such as fatigue, sleep disturbance or poor concentration [63].”
Background
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.